<DOC>
	<DOCNO>NCT00359229</DOCNO>
	<brief_summary>Primary objective : 1 . To evaluate efficacy Zolpidem 5mg 1 week elderly patient insomnia China Secondary objective : 1 . To evaluate safety Zolpidem 5mg 3 week elderly patient insomnia China . 2 . To evaluate efficacy Zolpidem 5mg 3 week elderly patient insomnia China</brief_summary>
	<brief_title>Stilnox Treatment Elderly Patients With Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Primary outpatient insomniac patient define DSMIV criterion Insomnia history last least 3 month , history must include selfreported usual sleep latency 30 minute either 3 awakening per night average usual total sleep time â‰¤6.5 hour Usage hypnotic within previous 13 week inclusion depend halflife hypnotic would affect study effect Concomitant usage hypnotic ( benzodiazepine Nonbenzodiazepines ) course study . Concomitant usage follow Central Nervous System active medicine : antipsychotic , antidepressant , anxiolytic , lithium psychotropic drug . The score Hamilton Depression Rating Scale ( HAMD24 ) 17 . The score Hamilton Anxiety Rating Scale ( HAMA14 ) 14 . Patients know hypersensitivity Stilnox ingredient product Patient severe respiratory insufficiency Patients suffer sleep apnoea syndrome Patients know severe hepatic ( risk encephalopathy ) /or renal insufficiency , severe organ diseases Patients suffer severe myasthenia gravis Patients previous history drug abuse , drug dependence drug addiction Any disease state major psychiatric condition might affect study result The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>